0001415889-24-004666.txt : 20240221 0001415889-24-004666.hdr.sgml : 20240221 20240221173806 ACCESSION NUMBER: 0001415889-24-004666 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240216 FILED AS OF DATE: 20240221 DATE AS OF CHANGE: 20240221 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LOUMEAU ERIC J CENTRAL INDEX KEY: 0001239648 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37985 FILM NUMBER: 24661254 MAIL ADDRESS: STREET 1: C/O HOLLIS-EDEN PHARMACEUTICALS STREET 2: 4435 EASTGATE MALL STE.400 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ANAPTYSBIO, INC CENTRAL INDEX KEY: 0001370053 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 203828755 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10770 WATERIDGE CIRCLE, SUITE 210 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-362-6295 MAIL ADDRESS: STREET 1: 10770 WATERIDGE CIRCLE, SUITE 210 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: ANAPTYSBIO INC DATE OF NAME CHANGE: 20080828 FORMER COMPANY: FORMER CONFORMED NAME: ANAPTYS BIOSCIENCES INC DATE OF NAME CHANGE: 20060724 4 1 form4-02212024_100259.xml X0508 4 2024-02-16 0001370053 ANAPTYSBIO, INC ANAB 0001239648 LOUMEAU ERIC J C/O ANAPTYSBIO, INC. 10770 WATERIDGE CIRCLE, SUITE 210 SAN DIEGO CA 92121 false true false false CHIEF LEGAL OFFICER 1 Common Stock 2024-02-16 4 M 0 5000 14.02 A 8240 D Common Stock 2024-02-16 4 S 0 5000 25 D 3240 D Employee Stock Option (right to buy) 14.02 2024-02-16 4 M 0 5000 0 D 2029-12-05 Common Stock 5000 78000 D The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person dated September 15, 2023. The stock option vested and is exercisable as to 25% of the shares subject to the option on December 6, 2020, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. In addition to the remaining options to purchase 78,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 355,310 shares of common stock, which options vest according to their terms. /s/ Eric Loumeau 2024-02-21